Prevention of Cardiovascular Events with Pitavastatin is Associated with Increased Serum Lipoprotein Lipase Mass Level: Subgroup Analysis of the TOHO-LIP

Aim: To clarify the mechanism by which pitavastatin reduced cardiovascular (CV) events more effectively than atorvastatin in the TOHO Lipid Intervention Trial Using Pitavastatin (TOHO-LIP), the changes in (Δ) non-heparinized serum level of lipoprotein lipase mass (LPL mass) during administration of...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagayama, Daiji, Saiki, Atsuhito, Watanabe, Yasuhiro, Yamaguchi, Takashi, Ohira, Masahiro, Sato, Naoko, Kanayama, Mizuho, Moroi, Masao, Miyashita, Yoh, Shirai, Kohji, Tatsuno, Ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Atherosclerosis Society 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090481/
https://www.ncbi.nlm.nih.gov/pubmed/33642441
http://dx.doi.org/10.5551/jat.62141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090481/
https://www.ncbi.nlm.nih.gov/pubmed/33642441
http://dx.doi.org/10.5551/jat.62141

Ejemplares similares